GLP-1 Agonists: Semaglutide vs Tirzepatide vs Retatrutide
GLP-1 receptor agonists have transformed the weight management and metabolic health landscape. Semaglutide (Ozempic®/Wegovy®) was the breakthrough, Tirzepatide (Mounjaro®/Zepbound®) raised the bar with dual-agonism, and Retatrutide represents the next frontier as a triple agonist. All three reduce appetite and improve metabolic markers, but they differ meaningfully in mechanism, efficacy magnitude, side effect profiles, and regulatory status. This comparison helps you understand the evolving landscape.
This is a generational arms race in obesity medicine. Semaglutide (Ozempic/Wegovy) hits one receptor and delivers ~15% weight loss with proven heart benefit. Tirzepatide (Mounjaro/Zepbound) hits two receptors and delivers ~20% weight loss with better stomach tolerability. Retatrutide hits three receptors and hit ~24% in Phase II — but isn't approved yet. More receptors generally means more weight loss.
Semaglutide
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. In Phase III TRIUMPH-1 (NEJM, September 2026) the 12 mg dose produced 25.0% mean weight loss at 80 weeks, and TRIUMPH-2 (Lancet, September 2026) showed up to 18.8% in adults with obesity and type 2 diabetes. Lilly plans to file with the FDA in Q1 2027.
| Category | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Drug Class | GLP-1 receptor agonist (single agonist) | GIP/GLP-1 dual receptor agonist (twincretin) | GIP/GLP-1/Glucagon triple receptor agonist |
| FDA Status | FDA-approved for T2D (Ozempic®) and obesity (Wegovy®) | FDA-approved for T2D (Mounjaro®) and obesity (Zepbound®) | Phase 3 (TRIUMPH-1/2 published Sept 2026); not yet FDA-approved |
| Mechanism | Activates GLP-1 receptors → insulin secretion, appetite suppression, delayed gastric emptying | Activates both GIP and GLP-1 receptors → enhanced insulin response, greater appetite suppression, improved fat metabolism | Activates GIP, GLP-1, and glucagon receptors → appetite suppression + increased energy expenditure + enhanced fat oxidation |
| Average Weight Loss (Trials) | ~15–17% body weight (STEP trials, 68 weeks) | ~20–22.5% body weight (SURMOUNT trials, 72 weeks) | ~24% body weight (Phase II, 48 weeks at highest dose) |
| Effect on HbA1c | −1.5–1.8% (strong glycemic control) | −2.0–2.4% (superior glycemic control) | −2.0%+ (early data, comparable to tirzepatide) |
| Cardiovascular Benefits | Proven MACE reduction (SELECT trial) — 20% risk reduction | SURPASS-CVOT (NEJM 2025): non-inferior to dulaglutide on MACE in T2D (HR 0.92), superiority not shown; obesity outcomes trial SURMOUNT-MMO ongoing | TRIUMPH-3 CV results inconclusive; dedicated outcomes trial ongoing (completion ~2029) |
| Dosing Schedule | Once weekly subcutaneous injection (0.25–2.4 mg) | Once weekly subcutaneous injection (2.5–15 mg) | Once weekly subcutaneous injection (dose-finding ongoing) |
| GI Side Effects | Common: nausea (44%), diarrhea (30%), vomiting (24%) | Common but generally milder: nausea (31%), diarrhea (23%), vomiting (12%) | Similar to semaglutide; nausea, diarrhea, vomiting at higher doses |
| Muscle Mass Preservation | ~25–40% of weight lost is lean mass (a concern) | Better lean mass preservation than semaglutide in head-to-head data | Glucagon component may enhance fat-selective weight loss (early signal) |
| Effect on Liver Fat (MASLD) | Significant reduction in liver fat (∓65–70%) | Superior liver fat reduction vs semaglutide in SYNERGY-NASH | Glucagon receptor activation may provide additional hepatic benefit |
| Unique Advantage | Longest track record, proven CV benefit, widest availability | Greater weight loss, better GI tolerability, superior glycemic control | Triple mechanism may offer highest efficacy and metabolic benefit |
| Key Limitation | Lower ceiling of weight loss vs newer agents; GI side effects | Less long-term safety data than semaglutide | Not yet approved; Phase 3 TRIUMPH-1/2 published Sept 2026, FDA submission planned Q1 2027; limited long-term data |
In depth
An evolving class
The GLP-1 agonist landscape has reshaped obesity and diabetes medicine in less than a decade, and each generation of drug has moved the efficacy ceiling. Semaglutide was the breakthrough — a once-weekly injection that produced weight loss previously only achievable through surgery. Tirzepatide raised the bar by engaging a second receptor (GIP) on top of GLP-1. Retatrutide, still investigational, adds a third (glucagon). The pattern is clear: more receptors engaged, more weight loss, with each generation pushing into territory the previous generation couldn't reach.
How much weight loss to expect
Semaglutide's pivotal STEP trials delivered ~15–17% mean weight loss at 68 weeks in non-diabetic obesity. Tirzepatide's SURMOUNT trials delivered ~20–22.5% at 72 weeks — and in head-to-head (SURMOUNT-5), tirzepatide beat semaglutide by a clinically meaningful ~5–7 percentage points. Retatrutide's Phase II 48-week data showed ~24% weight loss at the highest dose, with the trajectory suggesting it hadn't plateaued — a remarkable result that the ongoing Phase III program will need to confirm. For context: these numbers are approaching the bariatric-surgery range, which reshuffles the treatment algorithm.
Side effects and tolerability
All three cause the classic GLP-1 side effect profile — nausea, vomiting, diarrhea, constipation — and all are worst during dose escalation. The counterintuitive finding is that tirzepatide is generally better tolerated than semaglutide despite being more effective. The GIP component appears to buffer GLP-1-induced nausea, which is a genuine mechanistic advantage rather than just marketing. Retatrutide's tolerability profile looks similar to semaglutide so far, though the triple mechanism adds new considerations (glucagon receptor activation affects glucose handling in ways still being worked out).
Cardiovascular and metabolic beyond weight
Semaglutide has the strongest cardiovascular evidence — the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in obese non-diabetics. Tirzepatide's SURPASS-CVOT (NEJM 2025) found it non-inferior to dulaglutide on major cardiovascular events in type 2 diabetes (HR 0.92), without showing superiority; its placebo-controlled obesity outcomes trial (SURMOUNT-MMO) is still running. Retatrutide's TRIUMPH-3 cardiovascular results were inconclusive, and its dedicated outcomes trial runs to about 2029. On liver fat — important for the growing MASLD population — tirzepatide outperformed semaglutide in SYNERGY-NASH, and retatrutide's glucagon component may add further hepatic benefit.
Bottom line
For most patients today the real choice is semaglutide vs tirzepatide, and it's a choice between good and better. If proven cardiovascular benefit is the priority (e.g., established heart disease, or obesity without diabetes where SELECT applies), semaglutide has the stronger data. If maximum weight loss and better GI tolerability matter most, tirzepatide wins. In practice, insurance coverage often decides between them. Retatrutide will likely redefine the top of the field once approved, but it remains investigational and not yet commercially available. All three require clinical supervision, and weight loss sustained beyond drug discontinuation still requires the nutrition-exercise-sleep foundation these medications don't replace.
These peptides are often used together. See our stack profiles for combination details.